Our team discovered that probiotic Bacillus coagulans specifically metabolizes dihydrotestosterone, treating hyperandrogenism-related diseases like androgenic alopecia, prostate disorders, and polycystic ovary syndrome (PCOS). Mouse studies confirmed significant serum dihydrotestosterone reduction and hair loss prevention. We＇re developing functional gut bacteria through interdisciplinary microbiota-hormone research to address excessive androgen levels regulated by enterohepatic circulation.

Our team developed the world＇s first androgen-metabolizing probiotic therapy for hyperandrogenism-related diseases. We isolated dihydrotestosterone-metabolizing Bacillus coagulans that can prevent and treat hyperandrogenic conditions. The team also identified microbial metabolic genes and completed mouse experimental validation. This technology has been patented and transferred to domestic biotechnology companies, ushering probiotic therapy into a new era of precision medicine.

We isolated Bacillus coagulans that specifically metabolize dihydrotestosterone, effectively reducing serum androgen equivalent. This technology creates new therapeutic pathways for hyperandrogenism conditions. Industrial applications include: (1) functional probiotic health foods for Taiwan＇s health market; (2) therapeutic microbial preparations; (3) postbiotic natural product development. We have completed patent applications and signed technology transfer agreements with 2 domestic companies.